Clinical Trial Update: Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ibrutinib before and after stem cell transplantation in relapsed or refractory diffuse large B-cell lymphoma (activated B-cell type). R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-09-30